VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding

VolitionRx Limited has officially launched the DETECSEPS project, focusing on the early detection of sepsis, with funding of approximately €6.3 million (~$7.3 million) from the French government. The project is part of the DETECSEPS Consortium, which includes partnerships with IHU SEPSIS, AP-HP, and HCL. Volition's Nu.Q® NETs Assay has been selected as the sole biomarker for this initiative, which aims to enhance sepsis detection capabilities in line with the France 2030 plan.